Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care — Olga Vaccaro (2019) | RDL Network
Cardiovascular Effects of Pioglitazone or Sulfonylureas According to Pretreatment Risk: Moving Toward Personalized Care
Article 2019 en
Authors
OV
Olga Vaccaro
GL
Giuseppe Lucisano
MM
Maria Masulli
Abstract
1 min read
It is possible to identify patients with type 2 diabetes early in the stage of their disease and who are largely free from evident CV disease in whom add-on pioglitazone to metformin confers CV protection as compared with SUs.
Petar Seferović, Mark C. Petrie, Gerasimos Filippatos, Stefan D. Anker, Giuseppe Rosano, Johann Bauersachs, Walter J. Paulus, Michel Komajda, Francesco Cosentino, Rudolf A. de Boer, Dimitrios Farmakis, Wolfram Doehner, Ekaterini Lambrinou, Yu. M. Lopatin, Massimo Piepoli, Michael J. Theodorakis, Henrik Wiggers, John Lekakis, Alexandre Mebazaa, Mamas A. Mamas, Carsten Tschöpe, Arno W. Hoes, Jelena P. Seferović,
Igor Codreanu, Vera Sali, Sergiu Gaibu, Luminița Suveică, Serghei Popa, Norberto Perico, Bogdan Ene‐Iordache, Sergio Carminati, John Feehally, Giuseppe Remuzzi
Discussion(0)
No comments yet. Be the first to comment.